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Hyperbilirubinemia in the newborn results not only in 
visible yellow discoloration of the skin but, in high con-
centration, may cause bilirubin encephalopathy. Such 
damage to the central nervous system may be subtle and 
not apparent for several years, as with visual-motor 
perceptive defects; or it may cause severe neurologic 
damage (Kernicterus)-even death. Sick and immature . 
infants are the most vulnerable to bilirubin toxicity. 
Although this condition affects nearly half of all new-
borns to some degree, only about 10% require treatment. 
Two methods of treatment are really effective in cor-
recting hyperbilirubinemia, exchange blood transfu-
sions, and/or phototherapy with light radiation in the 
blue part of the visible spectrum. 
If the rate of production of bilirubin is excessive or an 
infant's capacity to conjugate and excrete the pigment is 
deficient, bilirubin will accumulate in plasma, and will 
be taken up by other lipid-containing tissues, collagen, 
and (unless firmly bound to albumin) brain tissue. 
Many factors combine to raise plasma levels of biliru-
bin to toxic levels; for example, acidosis, sepsis, hypoxia, 
hemolysis, hypoalbuminemia, and certain competitive 
albumin· binders. 
Bilirubin is photolabile in vivo, and if the whole body 
is irradiated with visible light in the absorption band 
(450-490 nm) of bilirubin, the pigment will undergo pho-
tocatabolism. Under phototherapy bilirubin undergoes 
photoisomerization at the meso double-bond to confor-
mations less lipophyllic. It is now known that the major 
photo products of bilirubin IX-a are an unresolved mix-
ture of its E, Z and Z, E isomers, easily excreted by the 
liver. Thus, phototherapy will reduce the accumulation 
of bilirubin in skin and other tissues and in circulating 
plasma. 
Visible jaundice in the skin and sclerae of newborn infants is 
the result of hyperbilirubinemia, that is to say, concentrations 
of bilirubin in plasma that exceed 5-6 Trig/dl. This condition 
affects roughJy half of all infants born, to a greater or lesser 
degree, and is one of the very few symptoms in the neonate 
which itself may cause damage \lnrelated to the underlying 
illness. 
Bilirubin is a straight chain tetrapyrrole derived principally 
. from the breakdown of heme. This occurs when heme is catab-
olized, by oxidation of its alpha-methene bond, in the reticulo-
endothelial cells of the liver and spleen and bone marrow, as 
red blood cells age, are incompletely formed, or are for other 
reasons destroyed [1]. 
Bilirubin is a lipid-soluble, nonpolar ·pigment which enters 
the circulation ·in an unconjugated form and is bound largely to 
. aJbumin, and to a lesser extent to red celJ membranes, during 
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its transport. In the liver celJ it is normalJy taken up by protein 
Y, called ligandin [2], which binds organic ions, among its 
functions, and which holds the bilirubin molecule within the 
cytoplasm. In this location, bilirubin is normally conj ugated 
with glucuronic acid by UDP-glucuronyl transferase, and 
thence excreted in the bile. 
If the rate of production of bilirubin is excessive, or the 
capacity to conjugate and excrete the pigment is deficient, 
unconjugated bilirubin accumulates in the plasma and will b e 
taken up by other lipid-containing tissues and colJagen. Biliru-
bin is normalJy bound to albumin at 2 sites, a primary site with 
a binding constant of 3 X 107 (80% or more bound h ere), and a 
secondary site with binding constant of lOG [3]. This secondary 
site of weaker binding is occupied if the albumin: bilirubin ratio 
exceeds 1, or if other compounds compete for the stronge}-
primary site. If bilirubin is bound to albumin, whether conju-
gated or not, it will not cross the blood brain balTier and thus 
cannot damage cells of the CNS. However, if unbound, the 
entry of divalent bilirubin (acid) into neuronal membranes by 
binding to phospholipids in these structures will cause distor-
tion of the celJ, and by aggregating cause its eventual destruc-
tion [4]. 
Many factors combine to raise plasma levels of bilirubin in 
t he newborn, especially in immature infants and those smaiJ for 
their gestational age [5]: acidosis and h ypoalbuminemia (com-
mon in the premature) , hypoxia, hemolytic disease of the new-
born, dehydration, sepsis, certain drugs and antibiotics, steroids 
and other compounds which compete for binding sites on al-
bumin, red celJ enzyme deficiencies, etc. 
Whatever factors are at play to produce hyperbilirubinemia, 
the effect of levels above 9 mg/ dl in the immature infant and 
above 15 mg/dl in the full-term infant are potentially if no t 
actually damaging to the central nervous system [6-11]. 
This damage has been termed bilirubin encephalopathy, and 
may be expressed as visual-motor perceptive defects, alJ the 
way to deafness, cerebral palsy and other massive neurologic 
defects called "kernicterus," to actual death. It is these irre-
versible injuries to the brain that result from uncontrolled and 
elevated levels of bilirubin in the plasma that must be treated . 
Previous to the studies of Cremer, Perryman, and R ichards 
[12], which inaugurated the technique of photot herapy, the 
only effective treatment of neonatal hyperbilirubinemia was 
exchange transfusion [13]. Now, however, it is possible to reduce 
the plasma concentration of bilirubin by the whole body irra -
diation of the jaundiced infant with visible light. However, its 
spectral output must contain light in the range of 440-490 nm. 
in order to assure its absorption by bili.rubin attached to albu-
min, lipids and collagen, at a variety of plasma pH-generally 
absorption is 450-460 nm. Phototherapy units, banks of 8 to 10 
fluorescent lamps placed about 2 ft above the skin surface of 
infants, are effective ligh t sources. It is now known that there 
is a dose: response relationship of light and bilirubin photo-
breakdown [14-16], and that fluorescent light sources contain-
ing 420-470 nm wavelengths are more efficient than broad-
spectrum flu orescent lamps having an output of energy between· 
400 and 700 nm. with but one-quarter t he energy in the range 
of absorption of bilirubin. 
Since the discovery of phototherapy, much effort has gone 
into the determination of the actua l photocatabolism of biliru-
bin. It is clear today that, both in vitro and in vivo, bili.rubin 
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und ergoes a number of photochemical reactions that depend on 
the chemical environment [17]. The labili ty of bilirubin and the 
intermediate compounds of its photobreakdown complicates 
the determination of the pathway end-prod ucts. It is enough to 
say, however, that fo llowing the work of Ostrow et al [17-20] 
and Lightner, M cDonagh et al [21-24] we have conclusive 
evidence that under phototherapy, bilirubin undergoes photo-
isomerization at the meso double-bond to a conformation less 
lipophylic, a less internally h ydrogen bonded form . Thus, it is 
now known t hat the main photoproducts of IXa-bilirubin are 
an unresolved mixture of its E , Z a nd Z, E isomers (Fig 1) . 
The liver is able to excrete such isomers, and so the marked 
increase in the biliary excretion of unconjugated, as well as 
norm ally conjugated, forms of bilirubin and related bile pig-
men ts when both jaundiced rats [20, 25] and jaundiced babies 
[26] are irradiated with visible light of appropriate wavelength 
is now expla ined. 
P hototherapy has effects upon organ systems and profound 
influence on intrinsic biologic behavior as well as upon cellular 
and molecular events. It has been shown, for instance, t hat 
during phototherapy the sleep states of newborns is altered; 
that rapid eye movement (REM) sleep increases not only in 
frequency but duration, compared wi th infants in a normal 
nursery envir6nment [27]. It is believed that protein synthesis 
in neurones occurs mainly during periods of REM sleep, and 
one can hope that promotion of this state in the developing 
brain of the newborn is an advantage. 
Still another phenomenon of significance that is influenced 
by exposure of infants to visible ligh t is biologic rhythm. Plasma 
somatotropin (human growth hormone or HGH) is a repre-
sentative marker for biorhythms in the neonate. A series of 
studies [28- 30] showed the pattern of rise and fall of plasma 
HGH under conditions of cycled light: dark, constant nursery 
light, and constant phototherapy with eyes covered by Iight-
opaque shields. 
It was found that under cycled light with intervals of darkness 
or very dim illuminat ion, the newborn has an ultradian rhythm 
of 4 -6 hr interval and with a wide circadian rhythm peaking at 
midnigh t to 2:00 AM, as in the adult. Under constant nursery 
light, h owever, the major circadian rhythm disappears and only 
the 4-6 hr ultradian rhythms persist. Both cU'cadian and ultra -
dian rhythms of HGH, on the other hand, are obliterated in 
infants under phototherapy (Fig 2). 
These findings indicate that the common practice of keeping 
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FIG 1. Light converts bil iruoin IX-a (Z. Z) to photobilirubin IX-ex 
(E. Zl by turning one of the outer pyrrol rings at the double-bond. 
Photobilil"Ubin does not form an insoluble ac id, is nontoxic, and is 
excreted rapidly in the bile without conjugation. 
nurser ies constan tly illuminated can eliminate normal rhythms 
of growth hormone observed under cycled light ing. The erasure 
of a ll biorhythm of t his important developmental hormone 
during phototherapy is not physiologic: a lthough its temporary 
nature may not produce a long-term effect, it does delay the 
establishment of a biorhythm norma lly present in the first day 
of life, and the consequence of this is uncertain . 
Cer tain short- term effects of phototherapy indicate that fun-
damental metabo lic processes are vulnerable to visible light 
irradiation. Rubaltelli , et al [31] have shown that t he trypto-
phane- kynurenine pathway is disturbed because of the photo-
destruction of the metabolites of tryptophane. 
The normal concentration of riboflavine, vitamin B2, in whole 
blood is rapidly reduced by phototherapy of t he newborn (Fig 
3) [32]. The in vitro and in vivo reduction of riboflavine has 
been associated with reduction of erythl'ocyte glucose-6-phos-
phate dehydrogenase(G6PD) and glutathione reductase (GSH) 
[32-36]. When such enzyme deficiencies are essent ially light -
induced they lead to increased red cell breakdown and conse-
quent increase of plasma bilirubin rather than an expected 
phototherapeutic decrease. As riboflavine is an essential co-
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FIG 2. The effect of cycled light/ dark environments and constant 
phototherapy radiation upon plasma Human Growth Hormone in vivo. 
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FIG 3. Effect of phototherapy upon whole bloocll'iboflavine levels 
in newborn infants. 
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TABLE 1. Enzyme activity of perfused Gunn rat livers-Ilmol/gm 
Dark Light 
Enzyme 
jj jj Jj jj jj 
Am inopyrene 3,028 3.77 1.835 5.175 5.089 
de methylation 
Aniline 0.151 0.187 0.147 0.301 0.335 
dehydroxylation 
Cytochrome 0.435 0.442 0.387 0.608 0.762 
P450 
CytochYome 0.792 0.551 0.554 0.808 0.794 
b5 
Benzo (a) pyrene 0.569 0.772 0.351 0.924 1.743 
hydroxylation 
p-Nit rophenol 2.592 1.350 2.082 4.607 4.639 
glucuronidation 5.020 
enzym e for G6PD and GSH , its r eduction will inhibit r ed cell . 
r espiration a nd cause ultimate hemolysis. 
It has been proposed [37] t h at h yp erbilirubinemia may in-
hibi t cellular imm~ne r espo nses in m a n . Rubalte lli e t a l [38] 
s u pported this by demons trating th at t h e Iymphoprolifer a tive 
response to phy t oh e m aglutinin-M in ja undiced infa nts was 
inhibited in substra tes of a utologous plasm a, cont rary t o the 
norm a l respo nse in no nja undiced infa n ts and a dults . Howe ver , 
ligh t- irradia tio n of bilirubin did no t alter its inhibitory effect. 
The ir studies did not indicate, however tha t light itself in the 
a bsence of bilirubin h ad a ny a dverse effect (39). One may 
conclude t hat phototh er a py may not r everse bilirubin's inhibi-
tory e ffect upon cellular immune compet en ce, but it does not, 
on t he o ther hand, r educe the immunologic capacity of irradi-
ated infa nts. 
Anoth er example of the profound biologic influe nce of visible 
ligh t is its capacity t o inactivate purified DNA a nd t o kill 
bac te ria in cultures (40). The work of S peck and R osenluanz et 
al [41-42] h as shown that whe n DNA-bilirubin complex in 
m a mmalia n cells is irradia ted by visible ligh t of broad spectral 
ou tput th e bilirubin m oie ty is photoactivated. This causes a 
cleavage of bonds within the DNA. 
Perma n en t cellular da m age h as not yet been observed in the 
photoirra dia ted infa n t, but t he po te n t ial for injury to cells must 
be considered . 
It is possible th at light is a n e nzym e-inducer. UDP glucuronyl 
tr a nsferase activity in microsomes of rat liver cells h as been 
r eported [43] , and the photoactiva tion of cytochrome P448 has 
been dem o ns trated in liver cell cultures [44]. S isson e t al [45] 
h ave de m o nstrat ed in preliminary s tudies that in blue light 
(420-470 nm) irra diatio n o f p erfused G unn rat live rs several 
e nzym e activ ities were incr eased 40% or more. Those m easured 
were: (a ) cytochrome P450; (b) cytochrome b5; (c) p-nitrophe-
nol glucuronida tion ; (d) be nzo (a) pyrine and aniline hydroxyl-
ation ; and (e ) aminopyrine demethylation . 
T h ese findings h ave most in t riguing implications concerning 
t h e promot ion of drug m et a bolism in the neona te, who has 
generally sluggis h drug m et a bolizing abilit y . (Table ) . 
The use of visible light in the managem ent of hyperbilirubi-
n emia in the n ewborn h as been a singula rly successful treat-
m e n t and it h as been so easy to administ er tha t its acceptance 
h as been p erhaps t oo uncritical. Although ne ither perma n en t 
nor e ven serious side-effects have been observed , we should 
keep som e reser vations about t he ultima t e effects a nd safety of 
. photother a py. 
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